Glaukos to Present at Wells Fargo Healthcare Conference
Event summary
- Glaukos management to participate in Wells Fargo Healthcare Conference on September 9, 2026, at 3:00 p.m. ET in Boston.
- Live and archived webcast available on Glaukos Investor Relations website.
- Glaukos focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases.
- Company launched iDose® TR in 2024, a long-duration intracameral procedural pharmaceutical for glaucoma.
- Glaukos also markets the only FDA-approved corneal cross-linking therapy for keratoconus.
The big picture
Glaukos' participation in the Wells Fargo Healthcare Conference underscores its strategic focus on innovative ophthalmic therapies. The company's pipeline, including the iDose® TR and corneal cross-linking therapy, positions it as a key player in the treatment of chronic eye diseases. The conference presentation will likely provide insights into Glaukos' growth trajectory and competitive positioning in the ophthalmology sector.
What we're watching
- Product Pipeline
- How Glaukos' advancements in dropless platform technologies will impact its market position.
- Regulatory Approvals
- Whether the FDA-approved corneal cross-linking therapy will drive further growth in rare corneal disorder treatments.
- Market Dynamics
- The pace at which Glaukos can scale its novel therapies in the competitive ophthalmic market.